Chad A Newton1, Julia Kozlitina2, Jefferson R Lines2, Vaidehi Kaza3, Fernando Torres3, Christine Kim Garcia4. 1. Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. 2. Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas. 3. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. 4. Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: Christine.garcia@utsouthwestern.edu.
Abstract
BACKGROUND: Prior studies have shown that patients with pulmonary fibrosis with mutations in the telomerase genes have a high rate of certain complications after lung transplantation. However, few studies have investigated clinical outcomes based on leukocyte telomere length. METHODS: We conducted an observational cohort study of all patients with pulmonary fibrosis who underwent lung transplantation at a single center between January 1, 2007, and December 31, 2014. Leukocyte telomere length was measured from a blood sample collected before lung transplantation, and subjects were stratified into 2 groups (telomere length <10th percentile vs ≥10th percentile). Primary outcome was post-lung transplant survival. Secondary outcomes included incidence of allograft dysfunction, non-pulmonary organ dysfunction, and infection. RESULTS: Approximately 32% of subjects had a telomere length <10th percentile. Telomere length <10th percentile was independently associated with worse survival (hazard ratio 10.9, 95% confidence interval 2.7-44.8, p = 0.001). Telomere length <10th percentile was also independently associated with a shorter time to onset of chronic lung allograft dysfunction (hazard ratio 6.3, 95% confidence interval 2.0-20.0, p = 0.002). Grade 3 primary graft dysfunction occurred more frequently in the <10th percentile group compared with the ≥10th percentile group (28% vs 7%; p = 0.034). There was no difference between the 2 groups in incidence of acute cellular rejection, cytopenias, infection, or renal dysfunction. CONCLUSIONS: Telomere length <10th percentile was associated with worse survival and shorter time to onset of chronic lung allograft dysfunction and thus represents a biomarker that may aid in risk stratification of patients with pulmonary fibrosis before lung transplantation.
BACKGROUND: Prior studies have shown that patients with pulmonary fibrosis with mutations in the telomerase genes have a high rate of certain complications after lung transplantation. However, few studies have investigated clinical outcomes based on leukocyte telomere length. METHODS: We conducted an observational cohort study of all patients with pulmonary fibrosis who underwent lung transplantation at a single center between January 1, 2007, and December 31, 2014. Leukocyte telomere length was measured from a blood sample collected before lung transplantation, and subjects were stratified into 2 groups (telomere length <10th percentile vs ≥10th percentile). Primary outcome was post-lung transplant survival. Secondary outcomes included incidence of allograft dysfunction, non-pulmonary organ dysfunction, and infection. RESULTS: Approximately 32% of subjects had a telomere length <10th percentile. Telomere length <10th percentile was independently associated with worse survival (hazard ratio 10.9, 95% confidence interval 2.7-44.8, p = 0.001). Telomere length <10th percentile was also independently associated with a shorter time to onset of chronic lung allograft dysfunction (hazard ratio 6.3, 95% confidence interval 2.0-20.0, p = 0.002). Grade 3 primary graft dysfunction occurred more frequently in the <10th percentile group compared with the ≥10th percentile group (28% vs 7%; p = 0.034). There was no difference between the 2 groups in incidence of acute cellular rejection, cytopenias, infection, or renal dysfunction. CONCLUSIONS: Telomere length <10th percentile was associated with worse survival and shorter time to onset of chronic lung allograft dysfunction and thus represents a biomarker that may aid in risk stratification of patients with pulmonary fibrosis before lung transplantation.
Authors: Marc de Perrot; Robert S Bonser; John Dark; Rosemary F Kelly; David McGiffin; Rebecca Menza; Octavio Pajaro; Stephan Schueler; Geert M Verleden Journal: J Heart Lung Transplant Date: 2005-08-08 Impact factor: 10.247
Authors: Mark L Barr; Steven M Kawut; Timothy P Whelan; Reda Girgis; Heidi Böttcher; Joshua Sonett; Wickii Vigneswaran; David M Follette; Paul A Corris Journal: J Heart Lung Transplant Date: 2005-07-27 Impact factor: 10.247
Authors: Jason D Christie; Martin Carby; Remzi Bag; Paul Corris; Marshall Hertz; David Weill Journal: J Heart Lung Transplant Date: 2005-06-04 Impact factor: 10.247
Authors: Matthew R Morrell; Joseph M Pilewski; Cynthia J Gries; Matthew R Pipeling; Maria M Crespo; Christopher R Ensor; Samuel A Yousem; Jonathan D'Cunha; Norihisa Shigemura; Christian A Bermudez; John F McDyer; Adriana Zeevi Journal: J Heart Lung Transplant Date: 2014-08-23 Impact factor: 10.247
Authors: R C King; O A Binns; F Rodriguez; R C Kanithanon; T M Daniel; W D Spotnitz; C G Tribble; I L Kron Journal: Ann Thorac Surg Date: 2000-06 Impact factor: 4.330
Authors: T Kauke; N Kneidinger; B Martin; A Dick; C Schneider; R Schramm; G Meimarakis; G Preissler; O Eickelberg; V von Dossow; J Behr; R Hatz; C Neurohr; H Winter Journal: Tissue Antigens Date: 2015-07-23
Authors: Michael Y Shino; S Samuel Weigt; Ning Li; Vyacheslav Palchevskiy; Ariss Derhovanessian; Rajan Saggar; David M Sayah; Aric L Gregson; Michael C Fishbein; Abbas Ardehali; David J Ross; Joseph P Lynch; Robert M Elashoff; John A Belperio Journal: Am J Respir Crit Care Med Date: 2013-11-01 Impact factor: 21.405
Authors: Chad A Newton; David Zhang; Justin M Oldham; Julia Kozlitina; Shwu-Fan Ma; Fernando J Martinez; Ganesh Raghu; Imre Noth; Christine Kim Garcia Journal: Am J Respir Crit Care Med Date: 2019-08-01 Impact factor: 21.405
Authors: Simone Feurstein; Ayodeji Adegunsoye; Danijela Mojsilovic; Rekha Vij; Allison H West DePersia; Padma Sheila Rajagopal; Afaf Osman; Robert H Collins; Raymond H Kim; Steven D Gore; Peter Greenberg; Lucy A Godley; Zejuan Li; Daniela Del Gaudio; Hari Prasanna Subramanian; Soma Das; Tom Walsh; Suleyman Gulsuner; Jeremy P Segal; Aliya N Husain; Sandeep Gurbuxani; Mary-Claire King; Mary E Strek; Jane E Churpek Journal: Blood Adv Date: 2020-10-13
Authors: Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 13.569
Authors: Chad A Newton; Justin M Oldham; Carolyn Applegate; Nikkola Carmichael; Karen Powell; Dan Dilling; Shelley L Schmidt; Mary Beth Scholand; Mary Armanios; Christine Kim Garcia; Jonathan A Kropski; Janet Talbert Journal: Chest Date: 2022-03-23 Impact factor: 10.262
Authors: Iulia Popescu; Hannah Mannem; Spencer A Winters; Aki Hoji; Fernanda Silveira; Emily McNally; Matthew R Pipeling; Elizabeth A Lendermon; Matthew R Morrell; Joseph M Pilewski; Vidya Sagar Hanumanthu; Yingze Zhang; Swati Gulati; Pali D Shah; Carlo J Iasella; Christopher R Ensor; Mary Armanios; John F McDyer Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 30.528